Compare Expensify Inc (EXFY) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Stryker Corporation — how do they compare? Expensify Inc trades at $2.4 (market cap $208.82M), while Stryker Corporation trades at $277.34 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 508.8× Expensify Inc's market cap, and Stryker Corporation pays a 1.27% dividend while Expensify Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expensify Inc for 41 Days and Stryker Corporation for 21 Days on average.
| EXFY | SYK | |
|---|---|---|
Market Cap | $208.82M | $106.24B |
Volume | 456,102 | 2,982,001 |
Sector | Technology | Health |
52-Week High | $2.72 | $388.35 |
52-Week Low | $0.75 | $269.75 |
Typical Hold Time | 41 Days | 21 Days |
Enterprise Value | $148.44M | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expensify (EXFY) trades at $2.40, up 5.73% today, showing technical bullish momentum with positive moving averages. The company reported mixed quarterly results with recent beats but maintains negative profitability metrics. Recent business developments include strategic AI integrations and European expansion of its corporate card program, signaling growth initiatives despite ongoing net losses.
The outlook remains speculative with analyst consensus pointing to significant upside potential ($13.75 target) but fundamental challenges persist including negative margins and cash flow volatility. Key risks include execution on AI transition and competitive pressure in expense management software, while institutional sentiment leans bullish with 50% buy ratings.
Stryker (SYK) trades at $277.52, up 0.77% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279. Fundamentally, the company reported strong profitability with a 14.43% net income margin in 2026 and beat EPS estimates in two of the last three quarters. However, recent news highlights potential legal and manufacturing issues that have pressured investor sentiment.
The outlook is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities lie in SYK's robust earnings growth and market leadership in medical technology, but risks include ongoing legal investigations and persistent manufacturing challenges that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
